10-Q: Passage Bio Reports Q2 2024 Results, Outlicenses Key Programs to Gemma Biotherapeutics

Passage Bio announced its second quarter 2024 financial results and a strategic outlicensing agreement with Gemma Biotherapeutics for several key programs.

Summary

• Passage Bio reported a net loss of $15.99 million for the three months ended June 30, 2024, and a net loss of $32.7 million for the six months ended June 30, 2024.
• The company's research and development expenses decreased to $10.43 million for the three months ended June 30, 2024, and $21.965 million for the six months ended June 30, 2024, primarily due to reduced spending on certain programs and headcount reductions.
• General and administrative expenses also decreased to $6.51 million for the three months ended June 30, 2024, and $13.025 million for the six months ended June 30, 2024, due to reduced share-based compensation and headcount.
• Passage Bio entered into a series of sublicense agreements with Gemma Biotherapeutics, outlicensing PBGM01, PBKR03, and PBML04, and will receive an initial payment of $10 million for clinical product supply.
• The company expects its existing cash, cash equivalents, and marketable securities, combined with the initial payments from the Gemma agreements, to fund operations through the end of the second quarter of 2026.
• As of June 30, 2024, Passage Bio had $91.8 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made strategic moves to reduce costs and secure funding through outlicensing, it continues to incur significant losses and faces substantial risks in its development programs. The outlicensing deal is a positive, but the overall financial situation and dependence on a single clinical program temper the outlook.

Positives

• The company successfully outlicensed three programs to Gemma Biotherapeutics, generating an initial payment of $10 million and potential future milestone payments and royalties.
• Operating expenses, including research and development and general and administrative costs, have decreased significantly, reflecting cost-cutting measures.
• The company has sufficient cash runway to fund operations through the second quarter of 2026.
• The company received positive regulatory feedback on the clinical pathway to treating FTD-C9orf72 patients with PBFT02 and plan to initiate dosing in the first half of 2025.

Negatives

• The company continues to incur significant net losses, with a $32.7 million loss for the first half of 2024.
• The company has an accumulated deficit of $627.2 million as of June 30, 2024.
• The company is dependent on the success of PBFT02, its sole clinical-stage product candidate.
• The company has limited experience in designing and implementing clinical trials and has never conducted pivotal clinical trials.

Risks

• The company is dependent on the success of PBFT02, its sole clinical-stage product candidate, and may not be able to successfully develop and commercialize it.
• The company is early in its development efforts and faces risks associated with advancing product candidates through preclinical studies and clinical trials.
• Gene therapy is a novel technology, making it difficult to predict the time and cost of product candidate development and regulatory approval.
• The company relies on third-party manufacturers and may experience manufacturing problems that could delay development or commercialization.
• The company faces significant competition and may not be able to achieve regulatory approval before competitors.
• The company may not be able to obtain and maintain patent protection or other necessary rights for its products and technology.
• The company may be subject to product liability lawsuits, which could cause substantial liabilities and limit commercialization.
• The company's stock price may be volatile and fluctuate substantially, which could result in substantial losses for holders of its common stock.
• The company's ability to utilize its net operating loss carryforwards may be subject to limitation.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities, combined with the initial payments from the Gemma agreements, to fund operations through the end of the second quarter of 2026. The company plans to initiate dosing in the first half of 2025 for FTD-C9orf72 patients with PBFT02 and expects to obtain regulatory feedback on the clinical pathway to treating ALS patients with PBFT02 in the second half of 2024.

Management Comments

• The company is focused on advancing PBFT02 in FTD-GRN and other neurodegenerative diseases.
• The company is actively managing its expenses and prioritizing its programs.
• The company is seeking to leverage strategic collaborations to advance its pipeline.

Industry Context

The announcement reflects a trend in the biotechnology industry where companies are focusing on core assets and outlicensing programs to manage costs and prioritize development efforts. The outlicensing of the lysosomal programs to Gemma is a strategic move to focus on the company's lead program, PBFT02, and its potential in broader neurodegenerative diseases.

Comparison to Industry Standards

• The decrease in R&D spending is consistent with other biotech companies that have recently undergone restructuring or program prioritization.
• The outlicensing of programs is a common strategy for companies to generate non-dilutive funding and focus on core assets, similar to other biotech companies.
• The cash runway projection to the second quarter of 2026 is a positive sign for investors, as it provides a clear timeline for the company's financial stability.
• The company's focus on gene therapy for neurodegenerative diseases aligns with a growing trend in the biotech industry, with several companies pursuing similar approaches, such as Prevail Therapeutics Inc. (part of Eli Lilly & Co) and AviadoBio Ltd.

Legal Proceedings

• The company is currently a defendant in litigation with a former employee relating to a claim of breach of contract and violation of the Pennsylvania Wage Payment and Collection Law.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial situation and development risks.
• Employees may be affected by ongoing cost-cutting measures and potential future workforce reductions.
• Patients with neurodegenerative diseases may benefit from the company's development of new therapies, but clinical trial outcomes are uncertain.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Report updated safety and biomarker data from Cohort 1 patients in September 2024.
• Report 12-month follow-up data from Cohort 1 patients and interim data from Cohort 2 patients in the first half of 2025.
• Seek regulatory feedback on pivotal trial design in the second half of 2025.
• Initiate dosing in the first half of 2025 for FTD-C9orf72 patients with PBFT02.
• Obtain regulatory feedback on the clinical pathway to treating ALS patients with PBFT02 in the second half of 2024.

Key Dates

Keywords

gene therapy, clinical trials, neurodegenerative diseases, PBFT02, Gemma Biotherapeutics, outlicensing, financial results, research and development, biotechnology, orphan drug designation